Pharvaris (NASDAQ:PHVS) Trading Up 3.8% – Here’s Why

Shares of Pharvaris N.V. (NASDAQ:PHVS) traded up 3.8% during mid-day trading on Wednesday . The stock traded as high as $27.50 and last traded at $27.2580. 174,789 shares were traded during trading, an increase of 11% from the average session volume of 156,850 shares. The stock had previously closed at $26.25.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Oppenheimer upped their price objective on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Wednesday, December 3rd. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Guggenheim increased their price target on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Wedbush lifted their price objective on Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $40.56.

Pharvaris Stock Up 4.9%

The company has a market capitalization of $1.44 billion, a PE ratio of -8.58 and a beta of -2.80. The company has a 50-day moving average price of $24.56 and a two-hundred day moving average price of $22.65.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. As a group, equities analysts anticipate that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Several hedge funds have recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris during the 2nd quarter worth approximately $57,000. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pharvaris during the 3rd quarter valued at $75,000. Public Employees Retirement System of Ohio increased its holdings in shares of Pharvaris by 39.3% in the third quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock worth $156,000 after purchasing an additional 1,769 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.